Emergent BioSolutions (EBS) Jefferies Global Healthcare Conference 2026 summary

Business model and market positioning

• Focuses on biodefense and public health, partnering with governments globally on products for threats like smallpox, anthrax, botulism, and Ebola.

• Maintains significant barriers to entry through specialized manufacturing and expertise in live attenuated virus vaccines and handling dangerous pathogens.

• NARCAN is a leading product for opioid overdose, recently switched to over-the-counter status to improve accessibility.

• Products are primarily manufactured in the U.S. or USMCA-compliant facilities, minimizing tariff and pricing risks.

• Bipartisan support from the U.S. government for both biodefense and opioid overdose solutions.

Financial performance and turnaround strategy

• Initiated a multi-year turnaround in 2024, completing a stabilization phase with divestitures, cost reductions, and litigation settlements.

• EBITDA improved from negative in 2023 to $184M+ in 2024 and $205M+ in 2025.

• Q1 2026 revenue of $156M and EBITDA of $36M, both ahead of expectations.

• Cash balance and liquidity improved by $11M year-over-year; debt reduced by $110M gross and $122M net.

• Refinanced term loan, extending maturity to 2031 and reducing interest expense by 200 basis points.

Growth initiatives and innovation

• Investing in international business expansion, with international revenue rising to 37% of MCM business in Q1 2026.

• Four new government contract awards, including a $140M contract with Canada and additional contracts for smallpox and anthrax products.

• Launched NARCAN carrying case and multi-pack to improve accessibility and efficiency.

• Entered new business development deals, including licensing KLOXXADO (8mg naloxone) and RocketVax technology for next-gen virus vaccines.

• Restarted Canton, MA facility for Japanese encephalitis vaccine production and signed a multi-year manufacturing agreement for a type 1 diabetes product.